DEFA14A: NovaBay Pharmaceuticals Urges Stockholders to Vote on Asset Sale and Liquidation Proposals

NovaBay Pharmaceuticals is urging stockholders to vote in favor of the proposed sale of Avenova and the subsequent liquidation and dissolution of the company at the reconvened special meeting on December 18, 2024.

Summary

• NovaBay Pharmaceuticals is reconvening its Special Meeting of Stockholders on December 18, 2024, after it was adjourned on November 22, 2024.
• The company is seeking stockholder approval for two key proposals: the sale of its Avenova assets to PRN Physician Recommended Nutriceuticals, LLC, and the subsequent liquidation and dissolution of NovaBay.
• The asset sale is governed by an Asset Purchase Agreement dated September 19, 2024.
• The liquidation and dissolution will be carried out according to the Plan of Complete Liquidation and Dissolution of NovaBay, subject to the Board of Directors' discretion.
• ISS, a leading proxy advisory firm, recommends that stockholders vote in favor of both proposals.
• The company emphasizes the importance of every stockholder's vote, regardless of the number of shares owned.
• Stockholders are encouraged to vote as soon as possible, with telephone and internet voting options available.

Sentiment

Score: 2

Explanation: The document indicates the company is seeking to liquidate and dissolve, which is a negative outcome for shareholders. While the company is urging shareholders to vote, the overall sentiment is negative due to the company's impending dissolution.

Positives

• The company has secured a buyer for its primary asset, Avenova.
• A leading proxy advisory firm, ISS, recommends voting in favor of the proposals, suggesting they are in the best interest of shareholders.
• The company is providing multiple convenient ways for shareholders to vote, including telephone and internet options.

Negatives

• The company is seeking to liquidate and dissolve, indicating a cessation of operations as a going concern.
• The need to reconvene the meeting suggests that the initial vote may not have been successful.

Risks

• The failure to secure approval for the asset sale and liquidation could have significant negative consequences for the company and its shareholders.
• The liquidation process may not return the full value of the company's assets to shareholders.
• There is a risk that the dissolution process may encounter unforeseen challenges or delays.

Future Outlook

The company's future is contingent on the approval of the asset sale and liquidation proposals, with the intention to dissolve the company if approved.

Management Comments

• Justin M. Hall, CEO, urges stockholders to vote in favor of the proposals.
• The CEO emphasizes the importance of every stockholder's vote.
• The CEO offers to speak personally with stockholders about the business and proposals.

Industry Context

The proposed sale and liquidation suggest that NovaBay is facing challenges in its current business model and is seeking to realize value from its assets through a sale rather than continuing operations.

Comparison to Industry Standards

• It is not uncommon for pharmaceutical companies facing financial difficulties to sell assets or liquidate.
• The decision to liquidate suggests that the company has not been able to achieve sustainable profitability or growth in the competitive pharmaceutical market.
• The sale of Avenova is similar to other instances where companies divest assets to focus on core business or to generate cash.

Stakeholder Impact

• Shareholders will be impacted by the proposed sale of assets and the subsequent liquidation.
• Employees may be impacted by the dissolution of the company.
• Customers of Avenova may be impacted by the change in ownership.

Next Steps

• Stockholders need to vote on the proposed asset sale and liquidation.
• The Special Meeting of Stockholders will be reconvened on December 18, 2024.
• If approved, the company will proceed with the sale of Avenova and the subsequent liquidation and dissolution.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova, Asset Sale, Liquidation, Dissolution, Proxy Vote, Stockholders Meeting, PRN Physician Recommended Nutriceuticals, ISS